Open an account

Jaguar Health

JAGX · NASDAQ

$2.63−$0.19 (−6.74%)TodayMarket closed ·
Prev close $2.82

About JAGX

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 47 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Employees
49
Headquarters
San Francisco, California
Listed
May 13, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
jaguar.health

JAGX key statistics

Market cap
5.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.45M
Volume
268.75K
Open price
$2.75
High today
$2.82
Low today
$2.61
52 Week high
$1,160.25
52 Week low
$2.35

Jaguar Health (JAGX) at a glance

As of Oct 20, 2026, Jaguar Health (JAGX) shares are priced at $2.63, giving the company a market cap of 5.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.61 and $2.82. The current price is 0.8% above the day's low and 6.7% below its high.

Volume so far is 268.75K shares, below the average of 6.45M shares a day.

Over the past year Jaguar Health has ranged from $2.35 to $1,160.25, and now sits 0% of the way up that range.

Jaguar Health met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY26 it reported -$13.60 per share against an estimate of -$2.08.

JAGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 54.6% on average.

  1. Q1 FY24: reported -$3,675.00 per share against an estimate of -$1,606.50
  2. Q2 FY24: reported -$3,535.00 per share against an estimate of -$1,071.00
  3. Q3 FY24: reported -$918.75 per share against an estimate of -$2,115.23
  4. Q4 FY24: reported -$11.90 per share against an estimate of -$660.45
  5. Q1 FY25: reported -$584.50 per share against an estimate of -$642.60
  6. Q2 FY25: reported -$359.10 per share against an estimate of -$254.54
  7. Q3 FY25: reported -$219.80 per share against an estimate of -$181.36
  8. Q1 FY26: reported -$13.60 per share against an estimate of -$2.08

JAGX news

  • Mohd Haider

    Jaguar Health (JAGX) Stock Climbs Over 34% After-Hours: What's Going On?

  • Henry Khederian

    Jaguar Health Stock Surges Friday: What's Happening?

  • Henry Khederian

    Jaguar Health Stock Slides Thursday: What's Happening?

  • Henry Khederian

    Jaguar Health Stock Plunges Wednesday: What's Happening?

  • Avi Kapoor

    Dow Falls 100 Points; General Mills Posts Upbeat Q1 Earnings

  • Shivdeep Dhaliwal

    Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today

  • Henry Khederian

    Jaguar Health Stock Slides Thursday: What's Happening?

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Similar companies

Companies in the same industry as Jaguar Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.